Quality of life evaluation in oncological clinical trials - The EORTC model

J. De Haes, D. Curran, T. Young, A. Bottomley, H. Flechtner, N. Aaronson, J. Blazeby, Kristin Bjordal, Y. Brandberg, E. Greimel, J. Maher, M. Sprangers, A. Cull

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The European Organization for Research and Treatment of Cancer (EORTC) has taken a leading role in the development of the methodology of quality of life (QL) measurement. In the EORTC Quality of Life Study Group (QLSG) valid instruments to assess QL in a general manner and disease-specific modules have been developed to be used in oncological clinical trials. Statistical and methodological aspects of QL research are discussed. The application of QL assessments in clinical trials represents a subsequent challenge. To improve the practice of QL assessment in clinical trials an 'EORTC model' has been developed. This model requires the collaboration of liaison persons, the EORTC Cooperative Tumour Groups and the EORTC Data Centre Quality of Life Unit (QL Unit). Cooperation between these parties, protocol development and advantages and concerns of the model are mentioned in this paper. Finally, suggestions for improvement are proposed. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)821-825
Number of pages5
JournalEuropean Journal of Cancer
Volume36
Issue number7
DOIs
StatePublished - May 1 2000

Fingerprint

Quality of Life
Clinical Trials
Organizations
Research
Neoplasms

Keywords

  • Liaison function
  • Protocol development
  • Quality of life assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

De Haes, J., Curran, D., Young, T., Bottomley, A., Flechtner, H., Aaronson, N., ... Cull, A. (2000). Quality of life evaluation in oncological clinical trials - The EORTC model. European Journal of Cancer, 36(7), 821-825. https://doi.org/10.1016/S0959-8049(00)00007-1

Quality of life evaluation in oncological clinical trials - The EORTC model. / De Haes, J.; Curran, D.; Young, T.; Bottomley, A.; Flechtner, H.; Aaronson, N.; Blazeby, J.; Bjordal, Kristin; Brandberg, Y.; Greimel, E.; Maher, J.; Sprangers, M.; Cull, A.

In: European Journal of Cancer, Vol. 36, No. 7, 01.05.2000, p. 821-825.

Research output: Contribution to journalArticle

De Haes, J, Curran, D, Young, T, Bottomley, A, Flechtner, H, Aaronson, N, Blazeby, J, Bjordal, K, Brandberg, Y, Greimel, E, Maher, J, Sprangers, M & Cull, A 2000, 'Quality of life evaluation in oncological clinical trials - The EORTC model', European Journal of Cancer, vol. 36, no. 7, pp. 821-825. https://doi.org/10.1016/S0959-8049(00)00007-1
De Haes J, Curran D, Young T, Bottomley A, Flechtner H, Aaronson N et al. Quality of life evaluation in oncological clinical trials - The EORTC model. European Journal of Cancer. 2000 May 1;36(7):821-825. https://doi.org/10.1016/S0959-8049(00)00007-1
De Haes, J. ; Curran, D. ; Young, T. ; Bottomley, A. ; Flechtner, H. ; Aaronson, N. ; Blazeby, J. ; Bjordal, Kristin ; Brandberg, Y. ; Greimel, E. ; Maher, J. ; Sprangers, M. ; Cull, A. / Quality of life evaluation in oncological clinical trials - The EORTC model. In: European Journal of Cancer. 2000 ; Vol. 36, No. 7. pp. 821-825.
@article{812d0a0fee6842cc90e628e8027bfc23,
title = "Quality of life evaluation in oncological clinical trials - The EORTC model",
abstract = "The European Organization for Research and Treatment of Cancer (EORTC) has taken a leading role in the development of the methodology of quality of life (QL) measurement. In the EORTC Quality of Life Study Group (QLSG) valid instruments to assess QL in a general manner and disease-specific modules have been developed to be used in oncological clinical trials. Statistical and methodological aspects of QL research are discussed. The application of QL assessments in clinical trials represents a subsequent challenge. To improve the practice of QL assessment in clinical trials an 'EORTC model' has been developed. This model requires the collaboration of liaison persons, the EORTC Cooperative Tumour Groups and the EORTC Data Centre Quality of Life Unit (QL Unit). Cooperation between these parties, protocol development and advantages and concerns of the model are mentioned in this paper. Finally, suggestions for improvement are proposed. Copyright (C) 2000 Elsevier Science Ltd.",
keywords = "Liaison function, Protocol development, Quality of life assessment",
author = "{De Haes}, J. and D. Curran and T. Young and A. Bottomley and H. Flechtner and N. Aaronson and J. Blazeby and Kristin Bjordal and Y. Brandberg and E. Greimel and J. Maher and M. Sprangers and A. Cull",
year = "2000",
month = "5",
day = "1",
doi = "10.1016/S0959-8049(00)00007-1",
language = "English (US)",
volume = "36",
pages = "821--825",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Quality of life evaluation in oncological clinical trials - The EORTC model

AU - De Haes, J.

AU - Curran, D.

AU - Young, T.

AU - Bottomley, A.

AU - Flechtner, H.

AU - Aaronson, N.

AU - Blazeby, J.

AU - Bjordal, Kristin

AU - Brandberg, Y.

AU - Greimel, E.

AU - Maher, J.

AU - Sprangers, M.

AU - Cull, A.

PY - 2000/5/1

Y1 - 2000/5/1

N2 - The European Organization for Research and Treatment of Cancer (EORTC) has taken a leading role in the development of the methodology of quality of life (QL) measurement. In the EORTC Quality of Life Study Group (QLSG) valid instruments to assess QL in a general manner and disease-specific modules have been developed to be used in oncological clinical trials. Statistical and methodological aspects of QL research are discussed. The application of QL assessments in clinical trials represents a subsequent challenge. To improve the practice of QL assessment in clinical trials an 'EORTC model' has been developed. This model requires the collaboration of liaison persons, the EORTC Cooperative Tumour Groups and the EORTC Data Centre Quality of Life Unit (QL Unit). Cooperation between these parties, protocol development and advantages and concerns of the model are mentioned in this paper. Finally, suggestions for improvement are proposed. Copyright (C) 2000 Elsevier Science Ltd.

AB - The European Organization for Research and Treatment of Cancer (EORTC) has taken a leading role in the development of the methodology of quality of life (QL) measurement. In the EORTC Quality of Life Study Group (QLSG) valid instruments to assess QL in a general manner and disease-specific modules have been developed to be used in oncological clinical trials. Statistical and methodological aspects of QL research are discussed. The application of QL assessments in clinical trials represents a subsequent challenge. To improve the practice of QL assessment in clinical trials an 'EORTC model' has been developed. This model requires the collaboration of liaison persons, the EORTC Cooperative Tumour Groups and the EORTC Data Centre Quality of Life Unit (QL Unit). Cooperation between these parties, protocol development and advantages and concerns of the model are mentioned in this paper. Finally, suggestions for improvement are proposed. Copyright (C) 2000 Elsevier Science Ltd.

KW - Liaison function

KW - Protocol development

KW - Quality of life assessment

UR - http://www.scopus.com/inward/record.url?scp=0034050177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034050177&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(00)00007-1

DO - 10.1016/S0959-8049(00)00007-1

M3 - Article

C2 - 10785585

AN - SCOPUS:0034050177

VL - 36

SP - 821

EP - 825

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -